Results 21 to 30 of about 698,336 (388)

A nomogram for predicting overall survival in patients with low‐grade endometrial stromal sarcoma: A population‐based analysis

Cancer Communications, 2020
Low‐grade endometrial stromal sarcoma (LG‐ESS) is a rare tumor that lacks a prognostic prediction model. Our study aimed to develop a nomogram to predict overall survival of LG‐ESS patients.
Jie Wu, Hui-bo Zhang, Lan Li, M. Hu, Liang Chen, Bin Xu, Q. Song   +6 more
semanticscholar   +1 more source

Histiocytic sarcoma [PDF]

Revista Brasileira de Hematologia e Hemoterapia, 2010
A 59-year-old white woman, SC, after being treated for pneumonia, presented with an increase in the size of lymph nodes. The immunohistochemical examination diagnosed histiocytic sarcoma. Relapse occurred 12 months after starting chemotherapy. The patient evolved with febrile neutropenia, septic shock and death.
Machado, Eduardo Silva, Miranda, Ana Carolina de, Escopelli, Ticiane, Caron, Ruggero, Escopelli, Alessandra Cristhina   +4 more
openaire   +5 more sources

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)

Frontiers in Oncology, 2023
BackgroundIntratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin and nivolumab may have synergistic effects in advanced sarcomas.Patients and ...
Sant P. Chawla, Walter Andree Tellez, Hripsime Chomoyan, Chrysler Valencia, Amir Ahari, Nadezhda Omelchenko, Stefan Makrievski, Don A. Brigham, Don A. Brigham, Victoria Chua-Alcala, Doris Quon, Ania Moradkhani, Erlinda M. Gordon, Erlinda M. Gordon   +13 more
doaj   +1 more source

Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment

ESMO Open, 2020
Background Imatinib is the standard first-line therapy in metastatic gastrointestinal stromal tumours (GIST). Investigational multi-kinase inhibitors (MKIs) such as nilotinib, dasatinib or masitinib have been tested as first-line therapies in phase II ...
Etienne Rouleau, Axel Le Cesne, Olivier Mir, Pierre Méeus, Julien Adam, Alice Boilève, Armelle Dufresne, Ali Chamseddine, Elise Nassif, Sarah Dumont, Medhi Brahmi, Marie Karanian, Véronique Haddad, Matthieu Faron, Charles Honoré   +14 more
doaj   +1 more source

Extra medullar Granulocytic sarcoma: a case report of an exceptional localization [PDF]

, 2020
Granulocytic sarcoma is a rare type of tumor composed of extramedullary immature cells. The breast location is very rare; it accounts for less than 8% of cases.
Khaled, Rahal, Malek, Bouhani, Olfa, Adouni, Olfa, Jaidane, Riadh, Chargui, Saida, Sakhri   +5 more
core   +2 more sources

Sarcoma treatment in the era of molecular medicine

EMBO Molecular Medicine, 2020
Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an ...
T. G. Grünewald, M. Alonso, S. Avnet, A. Banito, S. Burdach, F. Cidre‐Aranaz, Gemma Di Pompo, M. Distel, H. Dorado-García, J. García-Castro, Laura González-González, A. Grigoriadis, Merve Kasan, C. Koelsche, M. Krumbholz, F. Lecanda, Silvia Lemma, D. Longo, Claudia Madrigal-Esquivel, Álvaro Morales-Molina, J. Musa, S. Ohmura, B. Ory, Miguel Pereira-Silva, F. Perut, R. Rodríguez, Carolin Seeling, Nada Al Shaaili, S. Shaabani, Kristina Shiavone, Snehadri Sinha, E. Tomazou, M. Trautmann, M. Vela, Y. Versleijen-Jonkers, J. Visgauss, M. Zalacain, S. J. Schober, A. Lissat, W. English, N. Baldini, D. Heymann   +41 more
semanticscholar   +1 more source

Increased risk for other cancers in individuals with Ewing sarcoma and their relatives. [PDF]

, 2019
BackgroundThere are few reports of the association of other cancers with Ewing sarcoma in patients and their relatives. We use a resource combining statewide genealogy and cancer reporting to provide unbiased risks.MethodsUsing a combined genealogy of 2 ...
Abbott, Diana, Cannon-Albright, Lisa A, Farnham, James M, Jones, Kevin, Lessnick, Stephen L, O'Brien, Schuyler, Randall, R Lor, Schiffman, Joshua D, Yap, Jeffrey, Young, Erin L   +9 more
core   +1 more source

Age-related sarcoma patient experience: results from a national survey in England

BMC Cancer, 2018
Background Sarcomas are rare, heterogeneous tumours affecting patients of any age. Previous surveys describe that sarcoma patients report a significantly worse experience than those with common cancers.
Eugenie Younger, Olga Husson, Lindsey Bennister, Jeremy Whelan, Roger Wilson, Andy Roast, Robin L Jones, Winette TA van der Graaf   +7 more
doaj   +1 more source

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. [PDF]

, 2014
BackgroundIncreasing studies implicate cancer stem cells (CSCs) as the source of resistance and relapse following conventional cytotoxic therapies. Few studies have examined the response of CSCs to targeted therapies, such as tyrosine kinase inhibitors ...
Ames, Erik, Borys, Dariusz, Canter, Robert J, Chen, Mingyi, Grossenbacher, Steven K, Li, Chin-Shang, Mac, Stephanie, Monjazeb, Arta M, Murphy, William J, Sayers, Thomas J, Smith, Rachel C, Tellez, Joe   +11 more
core   +2 more sources

Rare aggressive behavior of MDM2-amplified retroperitoneal dedifferentiated liposarcoma, with brain, lung and subcutaneous metastases

Rare Tumors, 2016
Dedifferentiated liposarcoma (DDL) is a histologically pleomorphic sarcoma, traditionally defined as well-differentiated liposarcoma with abrupt transition to high grade, nonlipogenic sarcoma.
Imen Ben Salha, Shane Zaidi, Jonathan Noujaim, Aisha B. Miah, Cyril Fisher, Robin L. Jones, Khin Thway   +6 more
doaj   +1 more source